Advertisement

Clinical Drug Investigation

, Volume 39, Issue 8, pp 757–763 | Cite as

Emerging Trends in Metformin Prescribing in the United States from 2000 to 2015

  • Samantha Le
  • Grace C. LeeEmail author
Original Research Article
  • 53 Downloads

Abstract

Background

Metformin (MET) is used as first-line treatment for type 2 diabetes mellitus but has been shown to have pleiotropic effects that have expanded its use to various conditions. Limited current data exist regarding unconventional use within various patient populations.

Objective

The aim of this study was to evaluate US FDA-approved and off-label MET utilization in the US from 2000 to 2015.

Methods

We performed a retrospective analysis of outpatient MET prescribing in the US from 2000 to 2015. Data from the Medical Expenditure Panel Survey (MEPS) administered by the Agency of Healthcare Research and Quality were analyzed. Demographic characteristics, including age, sex, socioeconomic status, comorbidities, and region, were analyzed using the MEPS Household Component (HC). Prescription rates were defined as the annual number of MET prescriptions divided by the corresponding population estimate. Population denominators were derived using the MEPS HC. The MEPS estimates US populations based on sampled persons in the target population (civilian, non-institutionalized) for an entire year. MET prescribing is represented by population per 1000 persons. We determined if changes of MET prescribing were uniform across five age groups: < 18 years, 18–29 years, 30–49 years, 50–64 years, and 64 years and older.

Results

An estimated 553,291,094 MET prescriptions were dispensed in the US from 2000 to 2015. Prescribing rates steadily increased from 2000 to 2015. FDA-approved MET prescription rates increased from 2.27 per 1000 persons in 2000 to 235 per 1000 persons in 2015, while off-label MET prescription rates increased from 0.74 per 1000 persons in 2000 to 20.3 per 1000 persons in 2015. The top indications for off-label MET use were endocrine disorders (45.8%), cardiovascular disorders (18.2%), female reproductive disorders (12.9%), and metabolic disorders (10.9%). MET prescribing rates for FDA-approved indications increased across all age groups in 2000 and 2015, with the most substantial increase seen in adults aged 50–64 years and > 65 years (1.7 per 1000 persons to 20.6 per 1000 persons, and 2.3 per 1000 persons to 18.7 per 1000 persons, respectively). While off-label MET increased across all age groups from 2000 to 2015, a tenfold increase (< 1.0 to 10.6) was seen in adults aged 30–49 years of age.

Conclusion

Overall, MET use has substantially increased within the past 15 years, which was mainly driven by older adults. Our study highlights the emerging prevalence of MET use in both FDA-approved and off-label indications.

Notes

Compliance with Ethical Standards

Funding

No sources of funding were used for this study.

Conflicts of interest

Samantha Le and Grace C. Lee have no conflicts of interest to declare.

Ethics approval

This study is Institutional Review Board exempt.

Informed consent

Since this study analyzed anonymised data, no formal consent was required.

References

  1. 1.
    Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008;7(17):2769–73.CrossRefGoogle Scholar
  2. 2.
    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.CrossRefGoogle Scholar
  3. 3.
    Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol. 2010;6(3):457–70.CrossRefGoogle Scholar
  4. 4.
    Ruiter R, Visser L, van Herk-Sukel MP, Coebergh JW, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives. Diabetes Care. 2012;35(1):119–24.CrossRefGoogle Scholar
  5. 5.
    Libby G, Donnelly LA, Donnan PT, Alessi DR. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32(9):1620–5.CrossRefGoogle Scholar
  6. 6.
    King P, Peacock I, Donnelly R. The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999;48(5):643–8.CrossRefGoogle Scholar
  7. 7.
    Sharma M, Nazareth I, Petersen I, et al. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open. 2016;6:e010210.CrossRefGoogle Scholar
  8. 8.
    National Diabetes Statistics Report. 2017: estimates of diabetes and its burden in the United States. Atlanta: Centers for Disease Control and Prevention; 2017.Google Scholar
  9. 9.
    Kashi Z, Mahrooz A, Kianmehr A, Alizadeh A. The role of MET response in lipid metabolism in patients with recent-onset type 2 diabetes: HbA1c level as a criterion for designating patients as responders or nonresponders to MET. PLoS One. 2016;11(3):e0151543.CrossRefGoogle Scholar
  10. 10.
    Anurag P, Anuradha CV. MET improves lipid metabolism and attenuates lipid peroxidation in high fructose-fed rats. Diabetes Obes Metab. 2012;4(1):36–42.CrossRefGoogle Scholar
  11. 11.
    Nesti L, Natali A. MET effects on the heart and the cardiovascular system: a review of experimental and clinical data. Nutri Metab Cardiovasc Dis. 2017;27(8):657–69.CrossRefGoogle Scholar
  12. 12.
    Evans JM, Donnelly LA, Emslie-Smith AM, et al. MET and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304–5.CrossRefGoogle Scholar
  13. 13.
    Wang T, McNeill AM, Chen Y, Senderak M, Shankar RR, et al. MET prescription patterns among US adolescents aged 10-19 years: 2009–2013. J Clin Pharm Ther. 2016;41(2):229–36.CrossRefGoogle Scholar
  14. 14.
    Hsia Y, Dawoud D, Sutcliffe AG, Viner R, et al. Unlicensed use of MET in children and adolescents in the UK. J Clin Pharmacol. 2012;73(1):1365–2125.Google Scholar
  15. 15.
    Tahereh N, Bayat R, Hamedi M. MET therapy in girls with polycystic ovary syndrome: a self-controlled trial. Arch Iranian Med. 2007;10(2):176–81.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Pharmacotherapy, University of Texas at Austin College of PharmacyUT Health San AntonioSan AntonioUSA

Personalised recommendations